The recurrence and progression risk after simultaneous endoscopic surgery of urothelial bladder tumour and benign prostatic hyperplasia: a systematic review and meta‐analysis

• Published in: BJU international 2021-02, Vol.127 (2), p.143-152
• Main Authors: Sari Motlagh, Reza, Mori, Keiichiro, Miura, Noriyoshi, Quhal, Fahad, Aydh, Abdulmajeed, Laukhtina, Ekaterina, Pradere, Benjamin, Karakiewicz, Pierre I., Enikeev, Dmitry V., Deuker, Marina, Shariat, Shahrokh F.
• Format: Article
• Language: English
• Subjects: benign prostatic hyperplasia; Bladder; Bladder cancer; BladderCancer; blcsm; Clinical trials; Cystectomy - adverse effects; endoscopic surgery; Endoscopy; Genital diseases; Humans; Hyperplasia; Male; Meta-analysis; Neoplasm Recurrence, Local - diagnosis; Prostate; Prostatic Hyperplasia - diagnosis; Prostatic Hyperplasia - surgery; Review; Reviews; simultaneous surgery; Surgery; Systematic review; Transurethral Resection of Prostate - adverse effects; Tumors; TURBT; TURP; Urethra; Urinary Bladder - diagnostic imaging; Urinary Bladder Neoplasms - diagnosis; Urinary Bladder Neoplasms - surgery
• ISSN: 1464-4096; 1464-410X
• DOI: 10.1111/bju.15146

Objectives To evaluate recurrence and progression risk after simultaneous endoscopic surgery of bladder cancer and benign prostatic hyperplasia (BPH), as simultaneous surgery is not an unusual scenario and theoretically simultaneous transurethral resection of bladder tumour (TURBT) and transurethral resection of the prostate (TURP) can lead to an increased risk of recurrence in the bladder neck and prostatic urethra (BN/PU). Methods We conducted a systematic review and meta‐analysis to assess the risk of recurrence (i.e. whole bladder and/or BN/PU) and tumour progression as outcomes after a simultaneous endoscopic surgery of bladder tumour and BPH, as compared to TURBT alone. We queried PubMed and Web of Science database on 1 January 2020. We used random‐ and/or fixed‐effects meta‐analytic models in the presence or absence of heterogeneity according to the I2 statistic, respectively. Results Nine retrospective and three clinical trial studies were selected after considering inclusion and exclusion criteria. We conducted the meta‐analysis on retrospective and randomised controlled trials (RCTs) separately. Eight retrospective and three RCT studies were included to assess the BN/PU recurrence risk and the summarised risk ratio (RR) was 1.02 (95% confidence interval [CI] 0.74–1.41) and 0.93 (95% CI 0.47–1.84), respectively. Five retrospective and two RCT studies were included to assess the progression risk and the summarised RR was 0.91 (95% CI 0.56–1.48) and 1.16 (95% CI 0.30–4.51), respectively. Eight retrospective and three RCT studies were included to assess the whole bladder recurrence risk and the summarised RR was 0.87 (95% CI 0.78–0.97) and 0.89 (95% CI 0.65–1.21), respectively. Conclusion We did not observe any increased risk of total bladder recurrence, BN/PU recurrence, or progression after a simultaneous endoscopic surgery of bladder tumour and BPH, as compared to TURBT alone.